Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec;59(12):3783-3786.
doi: 10.1002/ppul.27231. Epub 2024 Aug 28.

Impact of nirsevimab on admission to a Spanish pediatric intensive care unit because of RSV bronchiolitis: Unicentric observational study from 2017 to 2024

Ana Espeleta-Fox  1 , Alberto García-Salido  2 , Almudena Vallespín-Casas  1 , Inés Leoz-Gordillo  1 , José Luis Unzueta-Roch  1 , Gema De Lama Caro-Patón  1 , María Ángeles García-Teresa  1 , Amelia Martínez de Azagra-Garde  1
Affiliations

Impact of nirsevimab on admission to a Spanish pediatric intensive care unit because of RSV bronchiolitis: Unicentric observational study from 2017 to 2024

Ana Espeleta-Fox et al. Pediatr Pulmonol. 2024 Dec.
No abstract available

Keywords: acute bronchiolitis; nirsevimab; pediatric intensive care unit; respiratory sincitial virus.

PubMed Disclaimer

References

REFERENCES

    1. Francisco L, Cruz‐Cañete M, Pérez C, et al. Nirsevimab para la prevención de la enfermedad por virus respiratorio sincitial en niños. posicionamiento de la sociedad española de infectología pediátrica. Anales de Pediatría. 2023;99:257‐263.
    1. Ahani B, Tuffy KM, Aksyuk AA, et al. Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials. Nat Commun. 2023;14:4347.
    1. Moline HL, Tannis A, Toepfer AP, et al. Early estimate of nirsevimab effectiveness for prevention of respiratory syncytial virus‐associated hospitalization among infants entering their first respiratory syncytial virus season ‐ new vaccine surveillance network, October 2023‐February 2024. MMWR Morb Mortal Wkly Rep. 2024;73:209‐214.
    1. Alharbi A, Yousef A, Zubani A, et al. Respiratory syncytial virus (RSV) burden in infants in the Kingdom of Saudi Arabia and the impact of all‐Infant RSV protection: a modeling study. Adv Ther. 2024;41:1419‐1435.
    1. Lopez‐Lacort M, Munoz‐Quiles C, Mira‐Iglesias A, et al. Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024. Euro Surveill. 2024;29(6):2400046. doi:10.2807/1560-7917.ES.2024.29.6.2400046

Grants and funding

LinkOut - more resources